Patients undergoing pancreaticoduodenectomy (PD) often require postoperative artificial nutrition. This trial was undertaken to evaluate whether the route of administration and the composition of the postoperative nutritional support could affect the immunometabolic response and outcome. A prospective, randomized trial was carried out in 212 subjects who underwent PD. Patients were randomized to receive a standard enteral formula (standard group, n ‫ס‬ 73) or an enteral formula enriched with arginine, omega-3 fatty acids, and RNA (immunonutrition group, n ‫ס‬ 71), or total parenteral nutrition (parenteral group, n ‫ס‬ 68). Postoperative feeding started 6 hours after surgery. The three regimens were isocaloric and isonitrogenous. Assessed parameters were phagocytosis ability of polymorphonuclear cells, plasma interleukin-2 receptors, Creactive protein, retinol binding protein, tolerance of enteral feeding, rate of postoperative complications, and length of hospital stay (LOS). Full nutritional goal (25 kcal/kg) was achieved in 87% of enterally fed patients versus 95% in the parenteral group. Subjects receiving immunonutrition had a significantly better recovery of the immunometabolic parameters on postoperative day 8 compared to the other two groups. The rate of postoperative complications was lower in the immunonutrition group (33.8%) than in either the standard (43.8%) or parenteral group (58.8%) (p ‫ס‬ 0.005 immunonutrition vs. parenteral). Also, the mean LOS was shorter in the immunonutrition group than in the standard and parenteral groups (15.1 vs. 17.0 vs. 18.8 days, respectively; p < 0.05). Early postoperative enteral feeding may safely and effectively replace parenteral nutrition in patients undergoing PD. Immunonutrition ameliorates the immunometabolic response and improves outcome compared to parenteral feeding. Key Words: Enteral nutrition-Parenteral nutrition-ImmunonutritionSurgery-Pancreatic resection-Cytokine-ImmunityPostoperative complications-Outcome.
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Pancreaticoduodenectomy (PD) is currently considered the treatment of choice for lesions of the pancreatic head, periampullary region, and duodenum. This surgical procedure is still aggravated by a considerable postoperative morbidity (1) (2) (3) (4) (5) that could delay postoperative resumption of adequate oral food intake. Moreover, cancer or chronic pancreatitis patients who are candidates for PD often have an associated comorbidity such as diabetes, jaundice, protein-energy undernutrition. Taken together, these issues represent an indication for artificial nutritional support (6) (7) (8) . Clinical experience focusing on postoperative feeding after major pancreatic resections is very limited (9, 10) . Nutritional choices after PD may be of particular interest because this operation affects both the endocrine and exocrine function of the gland, and the infusion of nutrients in the intestinal lumen may cause a stimulation of pancreatic and bile secretion. The present work was undertaken to evaluate whether early enteral nutrition may be a suitable alternative to total parenteral nutrition, and whether specialized enteral formulas could affect the immunometabolic response and improve outcome in patients homogeneous for this type of surgery. These hypotheses were addressed because in surgical patients both the advantages of enteral nutrition over parenteral feeding and the superiority of immuno-enhancing formulas over standard enteral diets remain a matter of debate (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) .
PATIENTS AND METHODS
Patients described in the present work represent a substantial extension of a subgroup of patients enrolled in previous trials (15, 17) . The Ethical Committee of our institute approved the protocol and written informed consent was obtained from all patients. Two hundred sev-enty-four patients, candidates for PD for lesion of either the pancreatic head or the periampullary region, were prospectively observed. Twenty-four patients were not eligible for prerandomization exclusion criteria as follows: two patients for creatinine level 3 mg/L; two patients for ascitis/portal hypertension; six patients for New York Heart Association class >3; seven patients for ongoing pulmonary or biliary infection; four patients for arterial PaO 2 <70 mm Hg; and three patients for preoperative radiochemotherapy. Thirty-eight patients were intraoperatively excluded for metastatic disease or unresectable primary tumor, and palliative surgery (biliary and/or gastrointestinal bypass) was advised. Two hundred twelve patients underwent curative procedures. Once PD was completed, randomization was performed using sealed envelopes. Patients were allocated into three study arms to receive (i) a standard enteral formula (standard group, n ‫ס‬ 73); (ii) an enteral diet enriched with arginine, omega-3 fatty acids, and RNA (Impact; Novartis Nutrition, Bern, Switzerland) (immunonutrition group, n ‫ס‬ 71); or (iii) total parenteral nutrition (parenteral group, n ‫ס‬ 68). The three regimens were processed to deliver the same amount of calories and nitrogen over a week of postoperative treatment.
The type of operation (pylorus-preserving PD or Whipple resection) and the type of management of the pancreatic stump (duct occlusion with Neoprene (22) or anastomosis) were left to the surgeon's preference. In all patients assigned to the enteral groups, a catheter-feeding jejunostomy (8Ch Kangaroo; Sherwood Medical, Tullemore, Ireland) was performed at the end of surgery before closing the wound (by a modified Witzel technique). A feeding tube was inserted into the peritoneal cavity through a small incision of the skin and of the abdominal wall at the left flank. Then, the third jejunal loop (30 cm aborally from the gastrojejunal anastomosis) was selected. A single pursestring suture was used, and the loop was perforated on the antimesenteric site and the catheter inserted into the jejunal lumen and advanced for 30 cm distally. The pursestring was closed around the entry site of the catheter. Then, the feeding tube was tunneled on the serosal site of the jejunum for 5 cm by several interrupted sutures. Finally, the jejunal loop was fixed at the peritoneum of the anterior abdominal wall with four interrupted sutures centered on the site of catheter entry into the abdominal wall. The feeding tube was flushed with 20 mL saline to check for lumen-free passage and leaking.
Infusion of the enteral diets started 6 hours postsurgery at a 10-mL/h rate. The velocity was progressively increased by 20 mL/d until reaching full nutritional goal (25 kcal/kg). Enteral or parenteral infusion was continued until the patient's oral intake was approximately 800 kcal/d. Glucose intolerance was defined as the need to correct hyperglycemia with insulin during artificial nutrition in nondiabetic patients.
Antibiotic prophylaxis was carried out using cefazolin sodium (2 g i.v.) during induction of anesthesia. A second dose was given 4 hours later. All patients received subcutaneous injection of low molecular weight heparin (50 IU/kg/d) as deep venous thrombosis prophylaxis: one dose 6 hours before surgery and one dose every day in the postoperative course. All patients received perioperative octreotide (0.1 mg, t.i.d., from 1 hour before surgery until the first day of oral diet resumption) in an attempt to decrease the occurrence of pancreatic fistula.
Members of the surgical staff not involved in the trial recorded postoperative complications. All infectious complications were proven by microbiologic analysis and positive fluid culture. The severity of postoperative infections was scored as described by Elebute and Stoner (23) . Relaporotomy, complications requiring patient transfer to intensive care, and interventional radiologic procedures were defined as major complications. Jejunostomy-related complications, abdominal cramps and distention, diarrhea (defined as more than three bowel movements per day), vomiting, and aspiration were considered adverse effects of early enteral nutrition. The first day of gas and feces passage was recorded in all patients.
In 30 consecutive patients per group, peripheral blood sampling (60 mL/patient) was obtained 1 day before surgery and on postoperative days (POD) 1 and 8. Fifty milliliters were used to evaluate the phagocytosis ability of polymorphonuclear cells (PMN) using the technique described by Brain and Kavet (24) . The magnitude of phagocytosis was expressed as the number of PMN in which zymosan particles were detected in per 100 PMNs. The remaining 10 mL of blood was centrifuged (2,000 rpm), the plasma divided in two aliquots, and frozen at −80°C until a batch analysis. Plasma interleukin-2 receptors (IL-2R; pg/mL) were measured by commercially available enzyme-linked immunosorbent assays (Genzyme Diagnostics, Cambridge, U.K.). Retinol binding protein (RBP; mg/mL) and C-reactive protein (CRP; g/L) were also measured 1 day before surgery and on PODs 1 and 8 in all patients.
Time variations of immunometabolic parameters and comparisons among the three groups were studied by repeated measure analysis of variance (ANOVA). Levels of significance were adjusted for multiple comparisons by the Student-Newman-Keul test. The nonparametric Mann-Whitney U test was used to analyze not normally distributed variables (blood loss and duration of surgery) and the 2 test for discrete parameters. Significance was
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defined at p < 0.05 (two-tailed test). Data are shown as mean (standard deviation). Statistical calculations were made using SPSS 7.5 package for Windows (SPSS Inc., Chicago, IL, U.S.A.).
RESULTS
The three groups of patients were closely comparable for preoperative characteristics (Table 1 ) and surgical parameters ( Table 2 ). The rate of malnutrition was approximately 40% and the mean plasma level of albumin was close to the minimum of the normal range (35-55 g/L). More than 50% of the patients required perioperative homologous transfusion, and preoperative jaundice was present in >60% of the patients. The most frequent disease was cancer of the pancreatic head followed by tumors of the periampullary region. Pylorus-preserving PD was performed more frequently than Whipple resection. Neoprene injection in the Wirsung duct was preferred to pancreaticojejunal anastomosis in the management of the pancreatic stump. Table 3 reports the time variation of immunometabolic parameters. No significant differences among groups for baseline values were observed for CRP, RBP, IL-2R, and PMN phagocytosis. CRP significantly rose on POD 1 in all groups, but on POD 8 the levels were significantly lower in the immunonutrition group compared to the other two groups. RBP had an opposite tendency with a reduction on POD 1 in all groups and a significant recovery on POD 8 only in patients fed with immunonutrition. IL-2R did not significantly change immediately after surgery. On POD 8, IL-2R levels were significantly higher than baseline only in the immunonutrition group. Surgery markedly impaired phagocytosis in all groups, but a significant recovery was found after 1 week of feeding only in the immunonutrition group.
Postoperative death rate was 3.3%. More patients died in the parenteral group than in the other two groups (p ‫ס‬ NS). Four patients died from cardiac failure, one from respiratory failure, one from hemorrhagic shock, and one from septic shock. Among the three groups, no statistical differences were found for major complications and/or noninfectious complications. The number of patients with any complication was significantly lower in the immunonutrition group than in the parenteral group (p ‫ס‬ 0.005; 2 ‫ס‬ 7.761). Moreover, patients fed with immunonutrition had lower rates and less severity of infectious complications (sepsis score) and shorter length of hospital stay than the other two groups ( Table 4 ). Details of complications are shown in Table 5 . Among the most frequent noninfectious complications were delayed gastric emptying, as previously defined (4), and pancreatic fistula. The mean (SD) duration of nasogastric intubation was 8.2 (3.3) days in the parenteral group, 7.4 (2.9) in the standard group, and 7.6 (2.9) in the immunonutrition group. Abdominal abscess and wound infection were the most frequent infectious complications.
The mean duration of artificial nutrition was 12.7 (4.8) days in parenteral group, 11.5 (4.6) in the standard group, and 11.8 (4.3) in the immunonutrition group. During this period, the mean (SD) caloric intake was 1,684 kcal (382), 1,538 (310), and 1,514 (337) in the parenter- Values are means (SD) or number of patients (%).
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al, standard, and immunonutrition groups, respectively. The first day of solid diet was 10.4 (3.7) in the parenteral group, 9.8 (3.8) in the standard group, and 10.0 (3.5) in the immunonutrition group. Twenty patients (37.7%) in the parenteral group experienced glucose intolerance versus nine patients (15.2%) in the standard group and nine patients (16.6%) in the immunonutrition group. Table 6 depicts the jejunostomy and early enteral nutrition-related complications. There was no significant difference between standard and immunonutrition groups, therefore the data from the two groups were pooled. Eighty-six patients (59.7%) experienced no adverse effects and the full nutritional goal was achieved by POD 4. Abdominal distention, cramps, diarrhea, and vomiting were observed in 58 patients (40.3%). Temporary lowering or discontinuation of the infusion rate allowed the symptoms to lessen in 39 patients. In these patients, the full nutritional regimen was reached after POD 5. Overall, the nutritional goal was reached in 125 patients (86.8%). No aspiration episodes or intestinal ischemia caused by infusion of nutrients in the gut lumen were observed. Bowel canalization to gas and feces in the pooled enterally fed patients occurred after 2.9 (1.0) and 4.4 (1.4) days, respectively, versus 3.8 (0.9) and 6.5 (1.7) days in the patients receiving parenteral nutrition (p < 0.05). Jejunostomy-related complications (tube clogging, dislodgment, and breakage) were rare (11 patients, 7.6%), and enteral infusion had to be permanently interrupted in only nine patients (6.2%). No jejunostomyrelated intestinal obstruction or ischemia was observed.
We also analyzed possible differences in tolerance of early enteral feeding in patients who underwent injection of Neoprene into the pancreatic stump, which completely abolished the exocrine pancreatic secretion (25, 26) , and in patients who underwent pancreaticojejunal anastomosis. Eighty-eight of the 133 (66.2%) patients treated with Neoprene and 55 of the 79 (69.6%) patients with anastomosis were randomized to enteral nutrition. The percentage of adverse effects (abdominal distention or cramps) was similar in the two groups (14.7 and 12.7%, respectively), whereas diarrhea occurred at a higher rate in patients treated with Neoprene (13.6%) than in the patients with anastomosis (7.3%) (P ‫ס‬ NS). This observation suggests that enzyme supplementation may be useful immediately after PD with duct occlusion.
DISCUSSION
Artificial nutrition in surgical patients is a procedure that has costs and some adverse effects and thus should be prescribed based on precise indications (6) (7) (8) . Based on our experience, we found that most patients undergoing PD fitted well with the previously cited guidelines. Nevertheless, little information is available on artificial nutrition after major pancreatic resection. In 1994, Brennan et al. (9) reported the first trial investigating the role of postoperative nutritional support in patients undergoing PD. They concluded that routine postoperative parenteral nutrition could not be recommended because increased complications were observed when compared to glucose infusion alone. The mean duration of total parenteral nutrition (12.3 days) was very similar to our find- Certainly an excessive amount of calories is more deleterious than permissive underfeeding (27) . Even though in our study, fewer calories were given and no unfed group was included, the routine use of total parenteral nutrition in this type of patient (mostly well nourished) does not seem to provide any benefit because the rate of postoperative complications appeared higher than expected (1) (2) (3) (4) (5) . This may be partially attributed to the high rate of glucose intolerance observed during total parenteral nutrition (28) .
Results from animal models of trauma strongly suggest that feeding the gut preserves its structure/function, maintains an effective local and systemic immune response, improves utilization of nutritional substrates and mesenteric blood flow/oxygenation, reduces hypermetabolic response, and increases survival (29) (30) (31) . These findings were the rationale to study the potential advantages of early enteral feeding over parenteral nutrition in patients undergoing major surgical procedures such as PD. Our data are not consistent with the findings of Watters et al. (32) , suggesting that early postoperative enteral nutrition was associated with reduced lung vital capacity, forced expiratory volume, and patient mobility and recovery. Lengths of intensive care unit and hospital stays were no different for patients receiving enteral nutrition or intravenous fluids. Details on outcome were not reported, so it was unclear whether the above-mentioned alteration of the respiratory mechanics were true pathophysiologic bases for potentially developing postoperative respiratory complications. In the present trial, enterally fed patients had fewer clinically relevant pulmonary complications, such as pneumonia, than parenterally fed subjects, and severe respiratory failure was observed in only one patient. One possible explanation is that we increased the velocity of enteral infusion more progressively than in the protocol of Watters et al., with the full nutritional goal to be reached on POD 4 rather than on POD 2.
The present work shows that the full nutritional regimen can be reached in most of the patients by the enteral route, at least by POD 5. Our data also suggest that in patients undergoing pancreaticoduodenectomy, enteral feeding does not increase the incidence of pancreatic and biliary fistula. This could have been one of the concerns of enteral infusion because of its possible stimulation on the exocrine pancreatic and bile secretion. Moreover, enteral nutrition promoted a faster recovery of bowel peristalsis as shown by the reduced time of canalization to gas and feces. The present experience confirms that jejunostomy is a safe procedure and an effective access for enteral feeding (33, 34) , and the rate of severe adverse effects, such as dislodgment, intestinal occlusion, and ischemia, were very low.
Van Berge Henegouwen and colleagues (10) performed a randomized trial showing that in patients undergoing pylorus-preserving PD, the use of cyclic infusion of enteral nutrients (stopped for 6 hours overnight) had some advantages over continuous (24 hours) enteral nutrition. Specifically, the patients receiving cyclic infusion had shorter nasogastric intubation times, quicker recoveries of normal diet intake, and shorter length of hospital stay. The population studied in this Dutch trial was similar to ours and the clinical results overlapped. They reported an overall postoperative morbidity of 35 versus 39% of our pooled enterally fed patients. We applied continuous enteral feeding, observing a longer duration of nasogastric intubation (7.5 vs. 6.7 days in the Dutch trial), a shorter recovery of the first day of normal diet after surgery (9.9 vs. 12.2 days), and a lower incidence of delayed gastric emptying (13 vs. 26%). It remains unclear why their patients needed 5.5 days to resume normal food intake after nasogastric tube removal.
In well-nourished subjects, cyclic enteral feeding may represent a good opportunity to reduce patient discomfort caused by night infusion. In contrast, it may represent a limitation when the full nutritional caloric and protein requirement needs to be reached, such as in malnourished or catabolic patients.
Recently, standard artificial nutrition has been modified by adding specific nutrients with the putative ability of modulating the immuno-metabolic response (35) (36) (37) . Based on experimental data (38) , several enriched diets have been tested in the clinical arena. The use of immuno-enhancing formulas appears to improve outcome in critically ill patients (39, 40) . Less clear is the advantage when given in the postoperative period in elective surgical patients undergoing major surgery for cancer. The initially positive results published by Daly et al. (13, 14) were only partially confirmed later (15) (16) (17) . In 1997, Heslin et al. (18) reported no significant outcome differences when patients (mostly undergoing PD) were treated with postoperative immunonutrition versus glucose infusion alone. It should be stressed that in this trial the two groups were somehow unbalanced: patients randomized to immunonutrition were potentially sicker than the control group by having more PD performed, longer anesthesia time, and higher incidences of preoperative chemotherapy. More important, the amount of immunoenhancing diet given in the postoperative course was quite limited. The mean volume over 10 postoperative days was approximately 300 mL per day. This is much less than what we achieved (1,500 mL) over a similar period. We speculate that the lack of clinical benefits shown by the trial of Heslin et al. may be, at least in part, attributed to the very limited amount of immunonutrients administered.
Our recent experiences (15, 17) with immunonutrition suggested a significant reduction of the severity of infectious complications and LOS, but not the rate of infectious complications, compared to others nutritional regimens. The present study was performed to understand whether similar results could be obtained in a more homogeneous cohort of patients undergoing the same surgical procedure. Overall, the data are consistent with those observed in patients subjected to different operations. In fact, patients receiving the enriched enteral diet had improved recovery of host defense mechanisms, better controlled inflammatory responses, and a reprioritization of protein synthesis (increased RBP and reduced CRP) compared to the other two groups. Moreover, reduced severity of infections and shorter length of hospital stay were confirmed. In contrast to what was previously shown (15, 17) , the present work also demonstrated a significant reduction in the rate of postoperative complications. These results might be attributed to first, all types of complications were included in the analysis (infectious and noninfectious) that also may be influenced by the type of nutrition. Second, we selected patients 
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with more severe perioperative comorbidity factors and who were undergoing more severe surgical procedures. We recently reported that even better results may be obtained by the administration of immunonutrients before and after surgery. This novel approach allows effective and immediate control of the surgery-related depression of the host defense and of the excessive inflammatory response and improves the intestinal perfusion and oxygen metabolism (41) (42) (43) . The results obtained indicate enteral feeding as the treatment of choice to nourish patients after PD. The administration of immunonutrition appears beneficial when given after severe surgical procedures and in highrisk surgical patients.
